Secretome Therapeutics Partner with Cellipont Bioservices to Manufacture Lead Therapeutic
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Secretome Therapeutics, a biotechnology company developing therapies based on neonatal cardiac progenitor cells (nCPCs), to support the cGMP manufacturing of Secretome’s lead asset, STM-01. As part of the collaboration, Cellipont Bioservices will oversee technology transfer, analytical method transfer, and cGMP manufacturing of the STM-01 Master Cell Bank. STM-01, an innovative nCPC product, is protected by a recently issued composition of matter patent.
Secretome Therapeutics Partner with Cellipont Bioservices to Manufacture Lead Therapeutic